Work

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-159636

Authors: Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Jean-Jacques Kiladjian, Stephen T Oh, Timothy Devos, Francesco Passamonti, Miklos Egyed, Alessandro Vannucchi, Andrzej Pluta, Donal P McLornan, Jun Kawashima, Mei Huang, Bryan Strouse, Claire Harrison

Institutions: The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, The University of Texas MD Anderson Cancer Center, University Hospital Leipzig, Leipzig University, University Health Network, Hadassah Medical Center, Centre for Biomedical Network Research on Rare Diseases, Centro de Investigación Biomédica en Red, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre d'Investigation Clinique Saint-Louis, Washington University in St. Louis, KU Leuven, University of Insubria, Somogy Megyei Kaposi Mór Oktató Kórház, Azienda Ospedaliero-Universitaria Careggi, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310163192

FWCI: 0.155

Cites:

Cited by: 1

Related to: 10